UTHR: United Therapeutics Corporation - Summary | Jitta

United Therapeutics Corporation

NASDAQ:UTHR

Price
$240.31
Loss Chance
47.6%
5.89JITTA SCORE
115.26%Over Jitta Line
Jitta Ranking
154 / 1,141
1,640 / 5,004
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (55)
Recent Business Performance (62)
Financial Strength (85)
Return to Shareholders (42)
Competitive Advantage (68)
Jitta Signs
Debt LevelLow Long Term Debt
Revenue and EarningEarning loss detected in 2019
Operating MarginInconsistent
SG&A to SalesIncreasing
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
5.89
115.26%
1.28
409.33%
2.03
332.54%
Biotechnology
5.65
233.35%
3.09
27.49%
3.09
27.49%
COMPANY DESCRIPTION
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.